Mutational analysis of microsatellite-stable gastrointestinal cancer with high tumour mutational burden: a retrospective cohort study

Keyphrases

• Retrospective Cohort Study 100%
• Mutational Analysis 100%
• Gastrointestinal Cancer 100%
• Microsatellite Stable 100%
• TMB-H 100%
• Microsatellite Instability-high (MSI-H) 100%
• Immune Checkpoint Inhibitors 100%
• Deficient Mismatch Repair (dMMR) 100%
• High Tumor mutation Burden 100%
• Tumor 80%
• Antitumor Immune Response 80%
• Research Fund 80%
• CARIS 60%
• China 40%
• Cyclin D1 (CCND1) 40%
• Immune Signature 40%
• Gastrointestinal Tumours 40%
• Mammalian Target of Rapamycin (mTOR) 20%
• Pancreas 20%
• Genomic Signature 20%
• Life Sciences 20%
• National Cancer Institute 20%
• Family Foundations 20%
• Drug Target 20%
• Molecular Alterations 20%
• Gene mutation 20%
• Science Foundation 20%
• Next-generation Sequencing 20%
• Janus Kinase 2 (JAK2) 20%
• Mismatch Repair 20%
• Peninsula 20%
• Hazard Ratio 20%
• Fisher's Exact Test 20%
• Tert 20%
• N-95 20%
• Survival Benefit 20%
• Smad2 20%
• Enhancer of Zeste Homolog 2 (EZH2) 20%
• Model Modification 20%
• Molecular Features 20%
• Log-rank Test 20%
• Gene Alteration 20%
• RAF1 20%
• Median Overall Survival 20%
• Kaplan-Meier Method 20%
• XPO1 20%
• Cancer Genome Atlas 20%
• Guilds 20%
• San Pedro 20%
• PTPN11 20%
• Kelch-like ECH-associated Protein 1 (Keap1) 20%
• Composite Biomarkers 20%
• Greggs 20%
• MAP2K4 20%
• Runt-related Transcription Factor 1 (RUNX1) 20%
• ErbB4 20%
• L-group 20%
• NFE2L2 20%
• PIK3R1 20%
• Sailing 20%
• RASA1 20%
• Peking University 20%
• MAP2K1 20%
• PPP2R1A 20%
• STAG2 20%
• Copy number Amplification 20%
• CDC73 20%
• Borges 20%
• National Natural Science Foundation of China 20%
• Innovative Talents 20%
• CTNNA1 20%
• PPP2R2A 20%
• Gene Signature 20%
• Tumor Environment 20%
• Predictive Model 20%
• Philip Pettit 20%
• Immune Cell Infiltration 20%
• Cancer Hospital 20%
• Memorial Sloan Kettering Cancer Center 20%
• High Status 20%

Medicine and Dentistry

• Retrospective Cohort Study 100%
• Immune Checkpoint Inhibitor 100%
• Mutational Analysis 100%
• Gastrointestinal Cancer 100%
• Tumor 100%
• Microsatellite Instability 100%
• Tumor Mutational Burden 100%
• Malignant Neoplasm 80%
• Immune Response 80%
• Gene Mutation 40%
• Gastrointestinal Tumor 40%
• Biological Marker 20%
• Immunocompetent Cell 20%
• Chromosome 20%
• Hazard Ratio 20%
• Cyclin D1 20%
• Fisher Exact Test 20%
• Overall Survival 20%
• DNA Mismatch Repair 20%
• Log Rank Test 20%
• Kaplan Meier Method 20%
• Next Generation Sequencing 20%
• Genomic Signature 20%
• The Cancer Genome Atlas 20%
• Janus Kinase 20%
• Drug Targeting 20%

Biochemistry, Genetics and Molecular Biology

• Cohort Study 100%
• Microsatellite Instability 100%
• Microsatellite 100%
• Immune Checkpoint Inhibitor 100%
• Immune Response 80%
• Gene Mutation 40%
• Next Generation Sequencing 20%
• Gene Signature 20%
• EZH2 20%
• KEAP1 20%
• PIK3R1 20%
• PTPN11 20%
• XPO1 20%
• Drug Targeting 20%
• Chromosome 20%
• Immunocompetent Cell 20%
• Overall Survival 20%
• DNA Mismatch Repair 20%
• MAP2K4 20%
• RUNX1 20%
• Genomic Signature 20%
• NFE2L2 20%
• ERBB4 20%
• MAP2K1 20%
• CDC73 20%
• Janus Kinase 20%
• Cyclin D1 20%
• Deficiency 20%